Evidence map›Paper›PMID 35748951›Full record

ArticleJournal of cancer research and clinical oncology2022

Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4

Xuedan Du, Jinting Wu, Ye Zhao, Bin Wang, Xiaobo Ding, Qiuyan Lin, Yingyu Chen, Jinduo Zhao, Lixiao Liu, Xiaolu Mao and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Xuedan Du *Department of Oncology, Lishui Central Hospital, Lishui, Zhejiang, People's Republic of China.
Jinting Wu *Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China.
Ye ZhaoDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Bin WangDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China.
Xiaobo DingDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China.
Qiuyan LinDepartment of Oncology, Ruian City People's Hospital, Wenzhou, Zhejiang, People's Republic of China.
Yingyu ChenDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Jinduo ZhaoDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Lixiao LiuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Xiaolu MaoDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China.
Zhen FangDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China.
Chunhong ZhangDepartment of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Wenfeng LiDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China. liwenfeng@wmu.edu.cn.ORCID http://orcid.org/0000-0002-8669-4976
Wenzhou Medical University · CNLishui Central Hospital · CN

Funding

National Natural Science Foundation of China No. 81871318Zhejiang Medical Association Clinical Research Project 2020ZYC-A115
6 · The paper itself

Abstract

methodsIn this study, we developed a strategy for the prevention and therapy of melanoma using a whole-cell vaccine combined with a CpG/αOX40/cGAMP triple adjuvant. The CpG/αOX40/cGAMP triple adjuvant was used to co-culture melanoma cells in vitro to induce immunogenic death of tumor cells. The mixture of inactivated tumor cells and the triple drug was an optimized tumor whole-cell vaccine, which was injected subcutaneously into mice for tumor prevention and therapy. Furthermore, we analyzed the changes of immune cells in spleen and tumor by flow cytometry and immunohistochemistry, and detected the changes of cytokines after vaccine application by cytometric bead array to explore the specific mechanism of vaccine.

resultsIn vaccine prevention and therapy experiments, it was observed that the tumor growth was significantly inhibited in the whole-cell vaccine group, and the survival time of mice was significantly prolonged. Flow cytometry results showed that the proportion of CD4+ T cells and CD8+ T cells in tumor of mice in vaccine group was higher than that in control group, especially the CD4+ T cells.

conclusionThe optimized vaccine has the unique ability to amplify tumor-specific CD4+ T cells, which improves antitumor sensitivity, and has a significant effect on the prevention and therapy of melanoma mice.

Indexed as

Cancer VaccinesMelanomaAdjuvants, ImmunologicAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesMiceMice, Inbred C57BLNucleotides, CyclicAdjuvants, ImmunologicCancer Vaccinescyclic guanosine monophosphate-adenosine monophosphateCytokinesNucleotides, CycliccGAMPCpGMelanomaOX40 agonistWhole-cell vaccines

Identifiers

PMID35748951
PMCPMC9587117
OpenAlexW4283398436

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.